Key clinical point: Managing comorbid psychiatric disorders in patients with MS could reduce the burden of functional GI disorders.
Major finding: Approximately 42% of patients with MS report functional GI disorders.
Study details: A survey of 6,312 participants in the North American Research Committee on MS Registry.
Disclosures: The study had no sponsor. Dr. Marrie had no disclosures, but other researchers had financial relationships with pharmaceutical companies, such as Merck, Novartis, Roche, Sanofi-Aventis, and Teva.
Marrie RA et al. CMSC 2019, Abstract QOL13.